Summary
BeOne Medicines Ltd. (ONC) reported a strong third quarter of 2025, with total revenues reaching $1.41 billion, a significant 41% increase year-over-year. This growth was primarily driven by robust performance in product revenue, which rose 40.4% to $1.395 billion, led by a remarkable 50.8% surge in BRUKINSA® sales, now exceeding $1 billion globally for the quarter. The company also demonstrated improved profitability, swinging from a net loss in the prior year period to a net income of $124.8 million. This financial turnaround, coupled with an increase in R&D investment and SG&A expenses, reflects BeOne Medicines' strategic focus on expanding its commercial reach and advancing its promising oncology pipeline.
Financial Highlights
47 data pointsBeta
Financial Statements
Beta
| Revenue | $1.41B |
| Gross Profit | $1.22B |
| R&D Expenses | $523.66M |
| SG&A Expenses | $529.00M |
| Operating Expenses | $1.05B |
| Operating Income | $163.11M |
| Interest Expense | $12.65M |
| Net Income | $124.84M |
| EPS (Basic) | $0.09 |
| EPS (Diluted) | $0.08 |
| Shares Outstanding (Basic) | 1.43B |
| Shares Outstanding (Diluted) | 1.49B |
Key Highlights
- 1Total revenues increased by 41.0% to $1.41 billion for Q3 2025 compared to $1.00 billion in Q3 2024.
- 2Net product revenue grew by 40.4% to $1.395 billion for Q3 2025, primarily driven by BRUKINSA® sales.
- 3Global BRUKINSA® revenue reached $1.04 billion in Q3 2025, a 50.8% increase year-over-year.
- 4Income from operations turned positive, reaching $163.1 million in Q3 2025, a significant improvement from a loss of $120.3 million in Q3 2024.
- 5Net income was $124.8 million for Q3 2025, compared to a net loss of $121.4 million in Q3 2024.
- 6Diluted EPS (ADS) was $1.09 for Q3 2025, a substantial improvement from a loss of ($1.15) per ADS in Q3 2024.
- 7The company reported strong cash and cash equivalents, totaling $4.11 billion as of September 30, 2025, indicating a healthy liquidity position.
Frequently Asked Questions
The primary driver of BeOne Medicines' revenue growth in Q3 2025 was the significant increase in net product revenue, which rose by 40.4% to $1.395 billion. This growth was predominantly fueled by the strong performance of BRUKINSA®, which saw its global revenue increase by 50.8% year-over-year to $1.04 billion.
BeOne Medicines demonstrated a significant improvement in profitability. The company swung from a net loss of $121.4 million in Q3 2024 to a net income of $124.8 million in Q3 2025. This turnaround was reflected in a positive income from operations of $163.1 million, a substantial improvement from a loss of $120.3 million in the prior year period.
BeOne Medicines maintains a strong liquidity position, with cash, cash equivalents, and restricted cash totaling $4.11 billion as of September 30, 2025. This robust cash balance provides significant financial flexibility for ongoing operations and strategic investments.
On August 25, 2025, BeOne Medicines entered into an agreement to sell royalty rights for IMDELLTRA® for up to $950 million, receiving an upfront payment of $885 million. This transaction significantly boosted the company's cash position but is recorded as a financing liability, with repayment tied to future royalty revenues. The liability was $885 million as of September 30, 2025, with $5.58 million in interest expense accrued in Q3 2025.